Tang Capital files 13G/A showing 0 shares in Ventyx
Ventyx Biosciences (Common Stock): Tang Capital affiliates filed an amended Schedule 13G/A stating they beneficially own 0 shares of common stock, representing 0% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Ventyx Biosciences (Common Stock): Tang Capital affiliates filed an amended Schedule 13G/A stating they beneficially own 0 shares of common stock, representing 0% of the class. The amendment lists entity relationships and addresses and is signed by Kevin Tang as manager and CEO.
Insights
Amendment reports no beneficial ownership across related entities.
The filing lists Tang Capital Management, related partnerships and corporations, and Kevin Tang, and states an aggregate beneficial ownership of 0 shares and 0% of the class. It documents addresses and citizenship for disclosure clarity.
Timing: the signatures are dated 05/15/2026. Cash‑flow and transaction activity are not described; subsequent filings would show any change in holdings.
Key Figures
Key Terms
Schedule 13G/A regulatory
Beneficially owned regulatory
CUSIP financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What entities are named in the Schedule 13G/A for VTYX?
What does the filing say about voting or dispositive power?
When was the amendment signed and by whom?
AI-generated analysis. How Rhea-AI works. Not financial advice.